ArticleCell reports. Medicine2026
Light-driven thermotropic hydrogel with nanomodulator enables lipid intervention and cavity delivery for postsurgical tumor therapy.
Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty acid-rich milieu is recognized as a potential key factor driving postsurgical tumor recurrence, while insufficient drug delivery to irregular surgical margins further compromises therapeutic effects. We find that this milieu directly drives lipid droplet accumulation in tumor-associated macrophages (TAMs), promoting M2 polarization, which can be reversed by rapamycin (Ra) via enhanced lipid droplet metabolism. Accordingly, we design a light-driven thermotropic hydrogel (LTG@RL) encapsulating a nanomodulator (R@LOX) containing lipoxygenase and Ra. Upon photothermal irradiation, LTG@RL undergoes reversible gel-sol transition for deep cavity penetration and sustained retention. R@LOX coordinates lipid intervention. It uses tumor-derived fatty acids to generate lipid peroxides, inducing ferroptosis in residual cancer cells, while repolarizing TAMs to the M1 phenotype to restore immune surveillance. In postsurgical melanoma and breast cancer models, LTG@RL suppresses tumor recurrence, prolongs survival, and also exhibits activity in non-surgical melanoma models. This strategy integrates lipid intervention and enhanced cavity delivery, offering precision prevention of postsurgical recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.